Rocaglamide (Rocaglamide A)

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

可选规格

包装

价格

促销价

数量
200ug

￥1090.00

981.00

- +
1mg

￥2500.00

2250.00

- +
5mg

￥7727.00

6954.00

- +
10mg

￥11888.00

10699.00

- +
25mg

￥24767.00

22290.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Rocaglamide是一种有效的NF-κB活化抑制剂。

货号：ajce51094
CAS：84573-16-0
分子式：C29H31NO7
分子量：505.56
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Rocaglamide is a potent NF-κB activation inhibitor.

Rocaglamide enhances TRAIL-induced apoptosis in resistant HCC cells. Treatment with Rocaglamide alone leads to apoptosis in 9% HepG2 and 11% Huh-7 cells and treatment with TRAIL induces apoptosis in 16% HepG2 and 17% Huh-7 cells. However, the combination of Rocaglamide and TRAIL induces apoptosis in 55% HepG2 and 57% Huh-7 cells, which is evidently more than an additive effect. A similar result is obtained by measurement of cell viability using crystal violet staining. Rocaglamide has the potential to sensitize highly chemoresistant HepG2 and Huh-7 cells to TRAIL-based therapy[2].

Tumor volumes in the Rocaglamide-treated group are 45±12% compared with the control group. Rocaglamide significantly suppresses tumor growth compared with that in the control group. Treatment with Rocaglamide does not lead to any reduction in body weight and no apparent signs of toxicity are observed in the mice during the treatment, suggesting that Rocaglamide is generally tolerated well[2].

Reference:
[1]. Santagata S, et al. Tight coordination of protein translation and heat shock factor 1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143): 1238303.
[2]. Luan Z, et al. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep